

FIG. 1




FIG. 2




Figure 3

Substance P & ESP7 Binding - Jan. 18




Figure 4

Intrathecal Administration




Figure 5.

0.2 ug ESP7+2CD (n=8)




Figure 6

0.05 ug ESP7+2CD (n=6)




Figure 7

**0.2ug ESP7+2CD - 0.2ug naltrexone
(Days 2&4)**




Figure 8

**1.0 ug ESP+2CD (Days1-5)- 250 pmol
RP67580 (Days 1-4) n=6**




Figure 9

0.1 ug ESP7+2CD (i.c.v) n=4




Figure 10

1 mg ESP7 (i.p.) n=7




Figure 11